Export 2761 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
A. Girach, Aiello, L. P., Milton, R. C., Davis, M. D., Danis, R. P., Zhi, X., Sheetz, M. J., and Vignati, L., “Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.”, Eye (Lond), vol. 23, no. 1, pp. 209-14, 2009.
A. Girach, Aiello, L., Milton, R., Davis, M., Danis, R., Zhi, X., Sheetz, M., Vignati, L., and Group, P. K. C. - D. R. S. 2Study, “Sustained Moderate Visual Loss as a Predictive End Point for Visual Loss in Non-Proliferative Diabetic Retinopathy”, Eye (Lond), vol. 23, pp. 209-214, 2009.
T. McLellan, Tai, B., and Gore-Langton, R., “Symposium: CTN Electronic Medical Records Project - Implication of Adopting Standardized Core-Date Elements in Health IT Systems of Drug Abuse Treatment Providers”, in American Psychological Association (APA) 119th Convention, Washington, DC, 2011.
M. Eydelman, Hilmantel, G., Tarver, M. E., Hofmeister, E. M., May, J., Hammel, K., Hays, R. D., and Ferris, F., “Symptoms and Satisfaction of Patients in the Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL) Studies.”, JAMA Ophthalmol, vol. 135, no. 1, pp. 13-22, 2017.
I. Hand, Boron, M., and Van Veldhuisen, P., “Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry”, 2001.
M. Hudak, Chartrand, S., and Registry, S. Outcomes, “Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection - Patient Dempgraphics and Preliminary Results from 2000-2001 Synagis® Outcomes Registry”, J Perinatology, vol. 21, pp. 500-501, 2001.
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
T
I. Tellez, Sabbaj, S., Peng, X., Mulligan, M. J., and AVEG], theN. I. H. A. I. D. S. V., “T cell and antibody responses in HIV-1 seronegative volunteers immunized with recombinant canarypox and gp120 prime-boost vaccines”, 1999.
S. M. Bartosh and Stablein, D. M., “Tacrolimus as primary immunosuppression for children receiving non-primary renal transplants: A report of the North American Pediatric Cooperative Study (NAPRTCS)”, 2000.
E. V. Maarseveen, Rogers, C., Trofe-Clark, J., Lghoul, F., Wong, M., Zuilen, A. V., Mudrikova, T., Barin, B., Stock, P., and Frassetto, L., “Tacrolimus Exposure and its Relation with Clinical Outcomes in HIV Infected Kidney Transplant Recipients on Antiretroviral Agents: An Area-Under-The-Curve Driven Analysis”, in World Transplant Congress, San Francisco, CA, 2014.
A. Krupnick, Serle, J., Van Veldhuisen, P., Lind, L., Clarke, J., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of eyelid dermatitis”, Cutis, vol. 73, pp. 267-71, 2004.
A. K. Freeman, Linowski, G. C., Brady, C., Lind, L., Van Veldhuisen, P., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas”, J Amer Acad Dermatology, vol. 48, pp. 564-8, 2003.
A. Krupnick Freeman, Linowski, G. J., Brady, C., Lind, L., VanVeldhuisen, P., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.”, J Am Acad Dermatol, vol. 48, no. 4, pp. 564-8, 2003.
M. Lebwohl, Freeman, A. Krupnick, M Chapman, S., Feldman, S. R., Hartle, J. E., and Henning, A., “Tacrolimus ointment is effective for facial and intertriginous psoriasis.”, J Am Acad Dermatol, vol. 51, no. 5, pp. 723-30, 2004.
M. Lebwohl, Freeman, A. K., Chapman, M. S., ,, J Hartle, M. P. H., Henning, A. K., and Group, T. Ointment S., “Tacrolimus Ointment is Effective for Facial and Intertriginous Psoriasis”, Journal of the American Academy of Dermatology, vol. 51, pp. 723-30, 2004.
G. W. Burke, Kaufman, D. B., Bruce, D. S., Sutherland, D., Johnson, C. P., Gaber, A. O., Merion, R. M., Schweitzer, E., Marsh, C. L., Gruber, S. A., Alfrey, E., Leone, J. P., Conception, W., Stegall, M. D., Gores, P. S., Danovitch, G., Nunnally, P. J., Henning, A. K., and Fitzsimmons, W. E., “Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) +/- antibody induction in simultaneous pancreas kidney (SPK) transplantation: one year results”, 2001.
A. M. Neu, Ho, P. L., Fine, R. N., Furth, S. L., and Fivush, B. A., “Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study”, Pediatric Transplantation, vol. 7, pp. 217-222, 2003.
A. M. Neu, Ho, P. L. Martin, Fine, R. N., Furth, S. L., and Fivush, B. A., “Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.”, Pediatr Transplant, vol. 7, no. 3, pp. 217-22, 2003.
A. M. Neu, Ho, M., Furth, S. L., Fine, R. N., and Fivush, B. A., “Tacrolimus vs. Cyclosporine as Primary Immunosuppression in Pediatric Renal Transplant Patients: a naprtcs study”, 2002.
A. M. Neu, Ho, P. L., Furth, S. L., Fine, R. N., and Fivush, B. A., “Tacrolimus vs. Cyclosporine as primary immunosuppression in pediatric renal transplant patients: a North American Pediatric Renal Cooperative Study (NAPRTCS) Report”, 2001.
J. Kobashigawa, Miller, L., Russell, S., Ewald, G., Zucker, M., Goldberg, L., Eisen, H., Salm, K., Tolzman, D., Gao, J., Fitzsimmons, W., First, M., and Investigators, S., “Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report”, Am J Transplant, vol. 6, pp. 1377-1386, 2006.
J. A. Kobashigawa, Miller, L. W., Russell, S. D., Ewald, G. A., Zucker, M. J., Goldberg, L. R., Eisen, H. J., Salm, K., Tolzman, D., Gao, J., Fitzsimmons, W., and First, R., “Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.”, Am J Transplant, vol. 6, no. 6, pp. 1377-86, 2006.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. H., Carter, S. L., Horowitz, M. M., and Antin, J. H., “Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT”, Blood, vol. 124, pp. 1372-1377, 2014.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W., Pasquini, M., MacMillan, M., Wingard, J., Waller, E., Grupp, S., McCarthy, P., Wu, J., Hu, Z., Carter, S., Horowitz, M. M., and Antin, J. H., “Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402”, in 54th Annual ASH Meeting, Atlanta, GA, 2012.